In vivo recovery of factor VIII and factor IX: Intra- and interindividual variance in a clinical setting

Haemophilia

Volumn 13, Issue 1, 2007, Pages 2-8

  Björkman, Sven ^a,b   Folkesson, A ^a,b   Berntorp, E ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Dosing; Factor IX; Factor VIII; In vivo recovery; Pharmacokinetics; Variance

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; KOGENATE BAYER; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG; WARFARIN;

AGE DISTRIBUTION; ARTICLE; CALCULATION; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE REGIMEN; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; LOW DRUG DOSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BLOOD COAGULATION TESTS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INFANT; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33845730827     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01401.x     Document Type: Article

References (23)

1. Messori A, Longo G, Matucci M, Morfini M, Rossi Ferrini PLR. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987; 13: 365-80.
2. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors. Clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
3. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005; 11: 571-82.
4. Aronstam A, McLellan DS, Wassef M, Mbhata PS. Effect of height and weight on the in vivo recovery of transfused factor VIII C. J Clin Pathol 1982; 35: 289-91.
5. Fukui H, Yoshioka A, Shima M et.al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. Int J Hematol 1991; 54: 419-27.
6. Kim HC, McMillan CW, White GC, Bergman GE, Saidi P. Clinical experience of a new monoclonal antibody purified factor IX: Half-life, recovery, and safety in patients with hemophilia B. Semin Hematol 1990; 27 (Suppl. 2): 30-5.
7. White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE, the Mononine Study group. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thromb Haemost 1995; 73: 779-84.
8. Ahnström J, Berntorp E, Lindvall K, Björkman S. A six-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-97.
9. Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
10. Rosén S. Assay of factor VIII:C with a chromogenic substrate. Scand J Haematol 1984; 33 (Suppl. 40): 139-45.
11. Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thrombos Haemost 1993; 70: 768-73.
12. Björkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994; 46: 325-32.
13. Carlsson M, Björkman S, Berntorp E. Multidose pharmacokinetics of factor IX: Implications for dosing in prophylaxis. Haemophilia 1998; 4: 83-8.
14. Hedner U, Nilsson IM. Methods. In: Nilsson IM, ed. Haemorrhagic and Thrombotic Diseases. London: John Wiley & Sons, 1974: 209-35.
15. Björkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 1992; 22: 385-95.
16. Shirahata A, Fukutake K, Takamatsu J, Shima M, Yoshioka A. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A. Int J Hematol 2000; 72: 101-7.
17. Feldschuh J, Enson Y. Prediction of the normal blood volume - relation of blood volume to body habitus. Circulation 1977; 56: 605-12.
18. Morfini M. Comparative pharmacokinetic studies in haemophilia. Haemophilia 2002; 8 (Suppl. 2): 30-3.
19. Linderkamp O, Versmold HT, Riegel KP, Betke K. Estimation and prediction of blood volume in infants and children. Eur J Pediatr 1977; 125: 227-34.
20. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: Implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
21. Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: A Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.
22. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
23. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9 (Suppl. 1): 101-10.